Introduction
Olomoucine and Roscovitine are drugs with an inhibitory effect on cyclin-dependent kinases (CDK). They are characterized by inhibiting CDK1, CDK2 and CDK5, but not CDK4 and CDK6. As a consequence, both compounds stop cell cycle and cell proliferation. In addition, apoptosis is also induced in many cell types. These cellular effects oppose neoplastic development and, as a consequence, neoplasia becomes an obvious target for these drugs (Knockaert et al., 2002) .
Little is known about the cellular events connecting drug-induced CDK dysfunction and apoptosis.
In order to investigate these events, we have characterized the apoptotic process triggered by Olomoucine (200µM) and Roscovitine (50µM) in SH-SY5Y cells (Ribas and Boix, 2004) . Our results have suggested the possibility of apoptosis being initiated at a membrane death receptor (Fas-like) and being transmitted by Caspase 8/10. However, Caspase8 and Caspase10 proteins are not expressed in SH-SY5Y cells because of gene silencing due to DNA methylation (Eggert et al., 2001) . Therefore, we hypothesized Olomoucine and Roscovitine could be inducing the re-expression of Caspase 8, Caspase 10 or both, thus triggering apoptosis from an undetermined death receptor. By means of Western blot studies and, particularly, by a kinetic analysis of Caspase 8/10 activation, this hypothesis has been ruled out.
Materials and Methods
Roscovitine and Iso-Olomoucine were purchased from Calbiochem (San Diego, CA, USA).
Olomoucine was acquired from Tocris (Bristol, UK). zVADfmk (Benzyloxycarbonyl-Val-Ala-Aspfluoromethylketone; Catalog # N-1510) was supplied by Bachem (Bubendorf, Switzerland). CellTiter 96® kit, containing the MTS reagent (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt), was provided by Promega (Madison, WI, USA). Cell viability (%) was measured by the capability of cells in culture to reduce MTS. Cell death (%) = 100 -cell viability (%). Louis, MO, USA). Secondary peroxidase conjugated antibodies were also from Sigma. Immunoblots were finally developed by means of the SuperSignal West Dura reagent from Pierce (Rockford, IL, USA).
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The kinetics and extent of effector Caspase activation (Caspase 3 and Caspase 7) was determined by the proteolysis of AcDEVDafc (Acetyl-Asp-Glu-Val-Asp-7-amino-4-(trifluoromethyl) coumarin), a fluorogenic substrate measuring DEVDase activity. Assays on cultured cells in 96 multiwell plates were performed as we have reported before (Yuste et al., 2001; Ribas and Boix, 2004) . The same procedure was applied to quantify the proteolysis of AcIETDafc (Acetyl-Ile-Glu-Thr-Asp-7-amino-4-(trifluoromethyl) coumarin), a fluorogenic substrate for either Caspase 8 or Caspase 10 (IETDase activity).
AcDEVDafc and AcIETDafc were obtained from Enzyme Systems Products (Livermore, CA, USA).
Results
In order to test if Olomoucine (200 µM) or Roscovitine (50 µM) were inducing apoptosis through the re-expression of Caspase 8 or Caspase 10 in SH-SY5Y cells, our first approach was to characterize the content of Caspase 8 and Caspase 10 zymogens in these cells facing these drugs. At 9 h of treatment most cells are either apoptotic or committed to apoptosis, this fact defined the time course shown in Fig.   1 . Even when films were overexposed, no band compatible with Caspase 8 zymogen was detected.
Concerning Caspase 10 zymogen detection, the lack of specificity of some commercial antibodies had been reported (Kischkel et al., 2001) . We tested some of those reported as specific and, indeed, they usually were in Jurkat extracts but not in SH-SY5Y ones (Fig. 1) . However, despite of the background, no band with the mobility expected for Caspase 10 zymogen was found. We wondered if the activation by proteolyisis of the zymogens could mask the re-expression of Caspase 8/10. To control this event, we repeated the time course analysis in the presence of 100 µM zVADfmk, a general inhibitor of caspases.
As seen in Fig. 1 , the presence of zVADfmk made no difference. In conclusion, neither Caspase 8 nor Caspase 10 seemed to be re-expressed upon Olomoucine or Roscovitine treatments.
To better support this result, we decided to perform an alternative approach, the kinetic analysis of caspase activation by these drugs (Fig. 2) . Caspase 8 and Caspase 10 share very similar affinities towards the aminoacids they target. The motif IETD is cleaved by both enzymes. As a consequence, the 6 cleavage and afc (7-amino-4-(trifluoromethyl) coumarin) fluorochrom release from the synthetic peptide Ac-IETD-afc, provides a method to detect and quantify Caspase 8/10 activation (IETDase activity).
Analogously, Caspase 3 and Caspase 7 show a similar affinity for the motif DEVD. Both are known to be effector caspases placed downstream of the apoptotic cascade of caspase activation. As a consequence, the fluorescence released by the cleavage of the synthetic peptide AcDEVDafc measures the activation of these effector capases (DEVDase activity). In addition, it indicates that apoptosis is taking place in the cell culture.
We proceeded to determine IETDase and DEVDase activities in SH-SY5Y cell cultures treated with either Olomoucine (200 µM) or Roscovitine (50 µM). As shown in Fig. 2 , apoptosis and DEVDase activity increased in a time-dependent manner while IETDase activity was absent. As a negative control, we assayed Iso-Olomoucine (200 µM), an inactive isomer of Olomoucine, and as expected IETDase and DEVDase activities remained at basal levels (not shown). SH-SY5Y cells were also treated with a Fas activating antibody (CH11 clone). Different antibody concentrations were tested up to 250 ng/ml and neither IETDase nor DEVDase activities were seen (Fig. 2) .
In order to control the specificity of our approach and the activity of the CH11 antibody, Jurkat cells were studied. Jurkat cells are known to posses a functional Fas system that induces apoptosis upon stimulation by this antibody. As seen in Fig. 2 , Caspase 8/10 dependent IETDase activity was already elevated at 6 h and decayed at 24 h, a time characterized by prominent cell destruction in the Jurkat culture. This result was consistent with the DEVDase activity profile from effector caspases, placed downstream of Caspase 8/10. In these cells, we thought of exploring the effects of Olomoucine (200 µM) and Roscovitine (50 µM). We found the profile of IETDase activity paralleled that of DEVDase one. Both activities increased in a time-dependent manner, thus emphasizing the near to zero value of the IETDase activity displayed by SH-SY5Y cells under the same treatment. In conclusion, Olomoucine and Roscovitine induce apoptosis in SH-SY5Y without the involvement of Caspase 8/10.
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In each experiment, the extent of cell death induced by a 24 h treatment was controlled by means of the MTS reduction assay. The ratios of cell death obtained in SH-SY5Y were: 58.8 ± 8.8% for Olomoucine, 46.7 ± 8.4% for Roscovitine and -5.5 ± 1.5% for CH11 antibody. In Jurkat cells, the ratios were: 59.6 ± 19.7%, 61.3 ± 9% and 70.5 ± 4.5% respectively. The values are the mean ± S.E.M. from the experiments comprised in Fig. 2 and were consistent with those expected (Ribas and Boix, 2004) .
Discussion
In this report, we have used two independent methods to demonstrate the null implication of Caspase 8 and Caspase 10 in the apoptotic pathways triggered by Olomoucine and Roscovitine in SH-SY5Y cells. In humans, Caspase 8 and Caspase 10 are constitutive elements of the apoptotic pathways initiated at cell membranes by death receptors, the so called extrinsic pathways (Ashkenazi and Dixit, 1998) . Therefore, the activation of a canonical, Caspase 8/10-mediated, extrinsic pathway is not the mode of action of two distinct CDK inhibitory drugs in this paradigmatic neuroblastoma cell line.
The procedure to determine caspase activation has been devised to be applied to multiwell plates (Yuste et al., 2001) . As a consequence, pharmacological approaches envisaging multiple simultaneous determinations are easily performed. However, the specificity of fluorogenic peptide substrates has been questioned. To be conclusive, we believe a negative control like Iso-Olomoucine for Olomoucine is required. To assess specificity, we suggest the use of a positive control of the caspase activation subjected to study. Jurkat cells and CH11 antibody have provided the positive control of Caspase 8/10 activation in our experiments. Moreover, Jurkat cells have also generated new information. First, Olomoucine and Roscovitine are effectively inducing apoptosis in this lymphoid cell line. Second, these drugs are activating Caspase 8/10 and, therefore, their involvement cannot be ruled out in these cells.
However, Caspase 8 has been reported to be activated downstream of Caspase 3 (Slee, et al., 1999) .
Therefore, Caspase 8/10 could merely be amplifying and not triggering the caspase cascade in Jurkat cells. In conclusion, Caspase 8/10 implication in apoptosis triggered by Olomoucine and Roscovitine in 8 Jurkat cells can be a matter of discussion and future research however, as emphasized before, it can be definitively discarded in SH-SY5Y cells. 
